Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Infectious Disease Transmission, Vertical | 27 | 2021 | 1351 | 1.180 |
Why?
|
HIV Infections | 68 | 2021 | 17337 | 1.110 |
Why?
|
Pregnancy Complications, Infectious | 31 | 2020 | 2149 | 1.090 |
Why?
|
HIV Protease Inhibitors | 12 | 2020 | 432 | 0.870 |
Why?
|
Anti-HIV Agents | 25 | 2021 | 4524 | 0.770 |
Why?
|
HIV-1 | 39 | 2020 | 6858 | 0.690 |
Why?
|
Postpartum Period | 13 | 2021 | 1178 | 0.370 |
Why?
|
HIV | 9 | 2021 | 1579 | 0.360 |
Why?
|
Viral Load | 21 | 2020 | 3325 | 0.360 |
Why?
|
Cytomegalovirus Infections | 5 | 2019 | 828 | 0.350 |
Why?
|
CD4 Lymphocyte Count | 17 | 2017 | 2567 | 0.340 |
Why?
|
Lymphocyte Count | 5 | 2019 | 778 | 0.310 |
Why?
|
Nelfinavir | 3 | 2015 | 68 | 0.300 |
Why?
|
Ritonavir | 6 | 2020 | 329 | 0.290 |
Why?
|
Pregnancy Trimester, Third | 11 | 2016 | 582 | 0.290 |
Why?
|
Pregnancy | 42 | 2021 | 29868 | 0.280 |
Why?
|
Antiretroviral Therapy, Highly Active | 13 | 2017 | 1894 | 0.280 |
Why?
|
Reverse Transcriptase Inhibitors | 4 | 2013 | 621 | 0.280 |
Why?
|
Pyrimidinones | 4 | 2010 | 385 | 0.270 |
Why?
|
Acquired Immunodeficiency Syndrome | 11 | 2017 | 2197 | 0.260 |
Why?
|
Stavudine | 1 | 2004 | 85 | 0.240 |
Why?
|
HIV Core Protein p24 | 5 | 2003 | 245 | 0.240 |
Why?
|
RNA, Viral | 12 | 2020 | 2838 | 0.240 |
Why?
|
HIV Integrase Inhibitors | 2 | 2018 | 165 | 0.230 |
Why?
|
Antibodies, Viral | 9 | 2015 | 3150 | 0.210 |
Why?
|
Herpes Simplex | 7 | 1997 | 465 | 0.210 |
Why?
|
Area Under Curve | 10 | 2020 | 1635 | 0.200 |
Why?
|
Organ Transplantation | 3 | 2022 | 1157 | 0.190 |
Why?
|
T-Lymphocytes, Cytotoxic | 7 | 2005 | 1779 | 0.190 |
Why?
|
Viremia | 4 | 2017 | 707 | 0.170 |
Why?
|
Adenine | 3 | 2013 | 985 | 0.160 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2021 | 149 | 0.160 |
Why?
|
Furans | 1 | 2020 | 202 | 0.160 |
Why?
|
Child | 44 | 2022 | 80079 | 0.160 |
Why?
|
Infant, Newborn | 31 | 2018 | 26180 | 0.160 |
Why?
|
Carbamates | 1 | 2020 | 191 | 0.150 |
Why?
|
Interleukin-1 | 4 | 1990 | 1248 | 0.150 |
Why?
|
Lymphoproliferative Disorders | 1 | 2022 | 531 | 0.150 |
Why?
|
Sulfonamides | 2 | 2020 | 1977 | 0.150 |
Why?
|
Immunoglobulins, Intravenous | 2 | 2017 | 664 | 0.150 |
Why?
|
Cytochrome P-450 CYP3A | 2 | 2016 | 114 | 0.150 |
Why?
|
Immunization, Passive | 2 | 2000 | 616 | 0.150 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 2 | 2010 | 244 | 0.150 |
Why?
|
Infant | 26 | 2021 | 36152 | 0.150 |
Why?
|
Dideoxynucleosides | 2 | 2010 | 135 | 0.150 |
Why?
|
Anti-Retroviral Agents | 2 | 2019 | 1782 | 0.150 |
Why?
|
Puerperal Infection | 3 | 2008 | 44 | 0.140 |
Why?
|
Adolescent | 39 | 2019 | 88234 | 0.140 |
Why?
|
Influenza A Virus, H1N1 Subtype | 2 | 2012 | 445 | 0.140 |
Why?
|
Nevirapine | 2 | 2008 | 273 | 0.140 |
Why?
|
Influenza, Human | 4 | 2012 | 1518 | 0.140 |
Why?
|
Oligopeptides | 2 | 2013 | 1185 | 0.140 |
Why?
|
Leukocytes, Mononuclear | 4 | 2014 | 1835 | 0.130 |
Why?
|
Cytomegalovirus | 4 | 2019 | 749 | 0.130 |
Why?
|
Child, Preschool | 29 | 2019 | 42188 | 0.130 |
Why?
|
Lymphocyte Subsets | 1 | 2017 | 310 | 0.130 |
Why?
|
Chickenpox Vaccine | 1 | 2015 | 40 | 0.130 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2022 | 612 | 0.130 |
Why?
|
Female | 78 | 2021 | 392148 | 0.130 |
Why?
|
Pregnancy Trimester, Second | 6 | 2016 | 730 | 0.120 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2018 | 287 | 0.120 |
Why?
|
Quinolones | 1 | 2018 | 378 | 0.120 |
Why?
|
Interferon-gamma | 5 | 2003 | 3145 | 0.120 |
Why?
|
Cyclohexanes | 1 | 2015 | 152 | 0.120 |
Why?
|
Rubella | 1 | 2015 | 55 | 0.120 |
Why?
|
Chickenpox | 1 | 2015 | 96 | 0.120 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2018 | 547 | 0.120 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2017 | 342 | 0.120 |
Why?
|
Mumps | 1 | 2015 | 71 | 0.120 |
Why?
|
Zidovudine | 6 | 2010 | 624 | 0.120 |
Why?
|
Gene Products, gag | 4 | 2005 | 312 | 0.120 |
Why?
|
Lymphocyte Activation | 6 | 2015 | 5463 | 0.120 |
Why?
|
Pyrrolidinones | 1 | 2014 | 116 | 0.120 |
Why?
|
Receptors, CCR5 | 1 | 2016 | 486 | 0.110 |
Why?
|
Young Adult | 24 | 2019 | 59179 | 0.110 |
Why?
|
JC Virus | 1 | 2014 | 87 | 0.110 |
Why?
|
Humans | 101 | 2022 | 760617 | 0.110 |
Why?
|
Epitopes, T-Lymphocyte | 4 | 2005 | 825 | 0.110 |
Why?
|
Proviruses | 1 | 2014 | 313 | 0.110 |
Why?
|
Measles | 1 | 2015 | 181 | 0.110 |
Why?
|
HIV Antibodies | 1 | 2000 | 1302 | 0.110 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2014 | 133 | 0.110 |
Why?
|
Immunity, Cellular | 5 | 2015 | 1550 | 0.100 |
Why?
|
Cohort Studies | 19 | 2021 | 41457 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 1992 | 4341 | 0.100 |
Why?
|
Influenza Vaccines | 2 | 2011 | 767 | 0.100 |
Why?
|
Antiviral Agents | 5 | 2012 | 3039 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 3 | 2015 | 1798 | 0.100 |
Why?
|
Saliva | 1 | 1997 | 828 | 0.100 |
Why?
|
Prospective Studies | 23 | 2021 | 54360 | 0.100 |
Why?
|
Simplexvirus | 5 | 1997 | 802 | 0.100 |
Why?
|
Adult | 42 | 2020 | 220969 | 0.100 |
Why?
|
Milk, Human | 2 | 2017 | 486 | 0.100 |
Why?
|
Monocytes | 3 | 1990 | 2565 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2001 | 1748 | 0.090 |
Why?
|
HIV Seropositivity | 1 | 1996 | 959 | 0.090 |
Why?
|
Immunocompromised Host | 3 | 2012 | 858 | 0.090 |
Why?
|
Drug Resistance, Viral | 1 | 2016 | 861 | 0.090 |
Why?
|
Virus Replication | 3 | 2011 | 2427 | 0.090 |
Why?
|
Pyridines | 2 | 2013 | 2874 | 0.090 |
Why?
|
Influenza A Virus, H5N1 Subtype | 1 | 2011 | 113 | 0.090 |
Why?
|
Plasma | 3 | 2018 | 586 | 0.090 |
Why?
|
Triazoles | 1 | 2015 | 903 | 0.080 |
Why?
|
Neutralization Tests | 3 | 2015 | 725 | 0.080 |
Why?
|
Leishmania donovani | 1 | 1990 | 68 | 0.080 |
Why?
|
Maternal Exposure | 1 | 2017 | 1067 | 0.080 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2005 | 1349 | 0.080 |
Why?
|
Leishmaniasis, Visceral | 1 | 1990 | 99 | 0.080 |
Why?
|
Metabolic Clearance Rate | 2 | 2011 | 361 | 0.080 |
Why?
|
Birth Weight | 1 | 2017 | 2101 | 0.080 |
Why?
|
Drug Therapy, Combination | 6 | 2013 | 6305 | 0.080 |
Why?
|
Influenza B virus | 1 | 2009 | 50 | 0.080 |
Why?
|
Infant, Very Low Birth Weight | 1 | 2011 | 407 | 0.080 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2009 | 83 | 0.080 |
Why?
|
Acute-Phase Proteins | 1 | 2009 | 250 | 0.080 |
Why?
|
Child Development | 1 | 2020 | 2300 | 0.080 |
Why?
|
Flaviviridae Infections | 1 | 2007 | 7 | 0.080 |
Why?
|
GB virus C | 1 | 2007 | 9 | 0.080 |
Why?
|
DNA, Viral | 4 | 2015 | 2195 | 0.080 |
Why?
|
Herpes Genitalis | 3 | 1996 | 149 | 0.070 |
Why?
|
United States | 16 | 2021 | 72272 | 0.070 |
Why?
|
Central Nervous System Diseases | 1 | 2012 | 521 | 0.070 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2018 | 5672 | 0.070 |
Why?
|
Oxidoreductases, N-Demethylating | 1 | 2007 | 109 | 0.070 |
Why?
|
Deoxycytidine | 1 | 2011 | 878 | 0.070 |
Why?
|
Half-Life | 3 | 2004 | 650 | 0.070 |
Why?
|
Lymph Nodes | 1 | 2018 | 3461 | 0.070 |
Why?
|
Papillomaviridae | 1 | 2013 | 1117 | 0.070 |
Why?
|
Papillomavirus Vaccines | 1 | 2013 | 496 | 0.070 |
Why?
|
Viral Vaccines | 1 | 2012 | 595 | 0.070 |
Why?
|
Hydrocortisone | 1 | 2014 | 1819 | 0.070 |
Why?
|
Pregnancy Trimesters | 2 | 2020 | 197 | 0.070 |
Why?
|
HIV Envelope Protein gp120 | 2 | 2001 | 914 | 0.070 |
Why?
|
Male | 40 | 2020 | 360358 | 0.070 |
Why?
|
Drug Administration Schedule | 6 | 2013 | 4845 | 0.060 |
Why?
|
Mitochondrial Diseases | 1 | 2010 | 343 | 0.060 |
Why?
|
Polymerase Chain Reaction | 5 | 2000 | 6074 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2019 | 4366 | 0.060 |
Why?
|
Infant, Premature, Diseases | 1 | 2011 | 710 | 0.060 |
Why?
|
Antibodies, Neutralizing | 2 | 2015 | 1936 | 0.060 |
Why?
|
Premature Birth | 1 | 2017 | 1782 | 0.060 |
Why?
|
Fetal Blood | 6 | 2016 | 1347 | 0.060 |
Why?
|
Respiratory Tract Infections | 1 | 2012 | 1009 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2015 | 3800 | 0.060 |
Why?
|
Puerto Rico | 2 | 2019 | 378 | 0.060 |
Why?
|
Viral Proteins | 3 | 2001 | 1799 | 0.060 |
Why?
|
Chromatography, Liquid | 2 | 2018 | 982 | 0.060 |
Why?
|
Tetanus | 1 | 2004 | 51 | 0.060 |
Why?
|
AIDS Vaccines | 2 | 2001 | 896 | 0.060 |
Why?
|
HIV Antigens | 2 | 2001 | 325 | 0.060 |
Why?
|
Chromatography, High Pressure Liquid | 4 | 2015 | 1540 | 0.050 |
Why?
|
Candida | 1 | 2004 | 171 | 0.050 |
Why?
|
Sepsis | 1 | 2017 | 2585 | 0.050 |
Why?
|
Lamivudine | 1 | 2004 | 366 | 0.050 |
Why?
|
Acyclovir | 2 | 1996 | 267 | 0.050 |
Why?
|
Amniotic Fluid | 1 | 2004 | 378 | 0.050 |
Why?
|
Immunosuppressive Agents | 2 | 2012 | 4174 | 0.050 |
Why?
|
Tandem Mass Spectrometry | 2 | 2018 | 1186 | 0.050 |
Why?
|
Prevalence | 5 | 2019 | 15689 | 0.050 |
Why?
|
Papillomavirus Infections | 1 | 2013 | 1611 | 0.050 |
Why?
|
HLA-A2 Antigen | 1 | 2001 | 209 | 0.050 |
Why?
|
Antigens, CD20 | 1 | 2022 | 199 | 0.050 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2019 | 4571 | 0.050 |
Why?
|
Tetanus Toxoid | 1 | 2021 | 188 | 0.050 |
Why?
|
Immunophenotyping | 2 | 2017 | 1865 | 0.050 |
Why?
|
Colitis, Ulcerative | 1 | 2013 | 1921 | 0.050 |
Why?
|
Vaccines, Synthetic | 2 | 2001 | 612 | 0.050 |
Why?
|
Treatment Outcome | 11 | 2016 | 64568 | 0.050 |
Why?
|
Crohn Disease | 1 | 2013 | 2279 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9172 | 0.040 |
Why?
|
Follow-Up Studies | 9 | 2017 | 39063 | 0.040 |
Why?
|
Ganciclovir | 1 | 2000 | 252 | 0.040 |
Why?
|
United States Health Resources and Services Administration | 1 | 2019 | 14 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2014 | 10754 | 0.040 |
Why?
|
Tissue Donors | 1 | 2009 | 2331 | 0.040 |
Why?
|
Naphthoquinones | 1 | 1999 | 58 | 0.040 |
Why?
|
Immunodominant Epitopes | 1 | 2000 | 238 | 0.040 |
Why?
|
Growth | 1 | 2001 | 365 | 0.040 |
Why?
|
Macrophages | 3 | 1988 | 5758 | 0.040 |
Why?
|
HIV Seronegativity | 1 | 2019 | 211 | 0.040 |
Why?
|
Encephalomyelitis, Acute Disseminated | 1 | 1998 | 68 | 0.040 |
Why?
|
Azithromycin | 1 | 1999 | 199 | 0.040 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2012 | 360 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4242 | 0.030 |
Why?
|
Kenya | 1 | 2019 | 757 | 0.030 |
Why?
|
Maternal Age | 1 | 2020 | 809 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2000 | 850 | 0.030 |
Why?
|
Administration, Oral | 3 | 2018 | 4010 | 0.030 |
Why?
|
Pregnancy Complications | 1 | 2010 | 2948 | 0.030 |
Why?
|
Skin Diseases, Viral | 1 | 1996 | 26 | 0.030 |
Why?
|
Enterococcus faecalis | 1 | 2017 | 245 | 0.030 |
Why?
|
Viral Tropism | 1 | 2016 | 102 | 0.030 |
Why?
|
Receptors, HIV | 1 | 2016 | 158 | 0.030 |
Why?
|
Oxazines | 1 | 2018 | 349 | 0.030 |
Why?
|
Phospholipases A | 1 | 1996 | 204 | 0.030 |
Why?
|
Prognosis | 5 | 2013 | 29600 | 0.030 |
Why?
|
Multivariate Analysis | 6 | 2011 | 12043 | 0.030 |
Why?
|
Cells, Cultured | 4 | 2000 | 18937 | 0.030 |
Why?
|
Incidence | 3 | 2020 | 21337 | 0.030 |
Why?
|
Eye Infections, Viral | 1 | 1996 | 60 | 0.030 |
Why?
|
Sampling Studies | 1 | 1996 | 615 | 0.030 |
Why?
|
Age Factors | 5 | 2014 | 18381 | 0.030 |
Why?
|
Infant, Premature | 2 | 2017 | 2107 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2019 | 22148 | 0.030 |
Why?
|
Immunity | 1 | 2001 | 994 | 0.030 |
Why?
|
Hospitalization | 3 | 2021 | 10704 | 0.030 |
Why?
|
Infant, Small for Gestational Age | 1 | 2017 | 462 | 0.030 |
Why?
|
Forced Expiratory Volume | 1 | 2019 | 1814 | 0.030 |
Why?
|
Herpesvirus 2, Human | 1 | 1996 | 191 | 0.030 |
Why?
|
Time Factors | 6 | 2012 | 39913 | 0.030 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2009 | 2423 | 0.030 |
Why?
|
Antifungal Agents | 1 | 1999 | 753 | 0.030 |
Why?
|
Seroepidemiologic Studies | 1 | 2015 | 397 | 0.030 |
Why?
|
Labor, Obstetric | 1 | 1997 | 323 | 0.030 |
Why?
|
Retrospective Studies | 10 | 2022 | 80566 | 0.030 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2014 | 61 | 0.030 |
Why?
|
Mouth Diseases | 1 | 1996 | 241 | 0.030 |
Why?
|
Blood Chemical Analysis | 1 | 2015 | 436 | 0.030 |
Why?
|
Encephalomyelitis, Autoimmune, Experimental | 1 | 1998 | 823 | 0.030 |
Why?
|
Paramyxoviridae Infections | 1 | 2012 | 57 | 0.030 |
Why?
|
Cognition | 2 | 2020 | 6987 | 0.030 |
Why?
|
Infant, Low Birth Weight | 1 | 2017 | 869 | 0.030 |
Why?
|
Pyridones | 1 | 2018 | 808 | 0.030 |
Why?
|
Concanavalin A | 1 | 1992 | 190 | 0.030 |
Why?
|
Adenovirus Infections, Human | 1 | 2012 | 73 | 0.030 |
Why?
|
Mothers | 2 | 2015 | 2194 | 0.030 |
Why?
|
Pediatrics | 1 | 2007 | 3588 | 0.020 |
Why?
|
Placenta | 1 | 2021 | 1709 | 0.020 |
Why?
|
Gestational Age | 2 | 2011 | 3577 | 0.020 |
Why?
|
Gene Frequency | 2 | 2010 | 3601 | 0.020 |
Why?
|
Disease Progression | 4 | 2003 | 13495 | 0.020 |
Why?
|
Immunity, Maternally-Acquired | 1 | 1992 | 111 | 0.020 |
Why?
|
Body Composition | 1 | 2001 | 2426 | 0.020 |
Why?
|
Risk Factors | 6 | 2017 | 74115 | 0.020 |
Why?
|
Receptors, CXCR4 | 1 | 2016 | 727 | 0.020 |
Why?
|
Blotting, Northern | 2 | 1990 | 1545 | 0.020 |
Why?
|
Immunization Schedule | 1 | 2012 | 227 | 0.020 |
Why?
|
Inhibitory Concentration 50 | 1 | 2011 | 465 | 0.020 |
Why?
|
California | 1 | 2015 | 1430 | 0.020 |
Why?
|
Age Distribution | 1 | 1996 | 2871 | 0.020 |
Why?
|
Antibody Affinity | 1 | 2011 | 246 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2013 | 883 | 0.020 |
Why?
|
Epitopes | 3 | 2003 | 2501 | 0.020 |
Why?
|
Amino Acid Sequence | 4 | 2003 | 13441 | 0.020 |
Why?
|
Anti-Bacterial Agents | 3 | 2017 | 7402 | 0.020 |
Why?
|
Weight Gain | 1 | 2000 | 2350 | 0.020 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2001 | 206 | 0.020 |
Why?
|
Intestine, Small | 1 | 1996 | 1207 | 0.020 |
Why?
|
Treatment Failure | 1 | 2016 | 2635 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2012 | 13635 | 0.020 |
Why?
|
Vidarabine | 1 | 1991 | 336 | 0.020 |
Why?
|
E-Selectin | 1 | 2011 | 577 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2014 | 1835 | 0.020 |
Why?
|
Chemokine CCL2 | 1 | 2011 | 602 | 0.020 |
Why?
|
Vaccination | 1 | 2001 | 3370 | 0.020 |
Why?
|
P-Selectin | 1 | 2011 | 599 | 0.020 |
Why?
|
Cross Reactions | 1 | 2011 | 816 | 0.020 |
Why?
|
Lymphotoxin-alpha | 1 | 1988 | 93 | 0.020 |
Why?
|
Obstetric Labor Complications | 1 | 1991 | 236 | 0.020 |
Why?
|
Europe | 1 | 2015 | 3413 | 0.020 |
Why?
|
Fibrinogen | 1 | 2011 | 887 | 0.020 |
Why?
|
Immunoglobulin A | 1 | 2011 | 978 | 0.020 |
Why?
|
Antigens, Viral | 1 | 1992 | 987 | 0.020 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2012 | 365 | 0.020 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2020 | 2518 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2011 | 753 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2011 | 1597 | 0.020 |
Why?
|
Piperazines | 1 | 2018 | 2521 | 0.020 |
Why?
|
HLA-D Antigens | 1 | 1987 | 129 | 0.020 |
Why?
|
Immunity, Humoral | 1 | 2011 | 600 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2016 | 4269 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 2011 | 770 | 0.020 |
Why?
|
HLA Antigens | 1 | 2012 | 1329 | 0.020 |
Why?
|
Alkynes | 1 | 2007 | 320 | 0.020 |
Why?
|
Linear Models | 1 | 1996 | 5866 | 0.020 |
Why?
|
Cyclopropanes | 1 | 2007 | 432 | 0.020 |
Why?
|
Benzoxazines | 1 | 2007 | 316 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2011 | 15498 | 0.020 |
Why?
|
RNA, Messenger | 3 | 1990 | 12758 | 0.020 |
Why?
|
Endotoxins | 1 | 1988 | 520 | 0.020 |
Why?
|
Molecular Sequence Data | 3 | 2003 | 17629 | 0.020 |
Why?
|
Coma | 1 | 2009 | 484 | 0.020 |
Why?
|
Cell Adhesion Molecules | 1 | 2011 | 1602 | 0.020 |
Why?
|
Pulmonary Alveoli | 1 | 1988 | 652 | 0.020 |
Why?
|
Lymphokines | 1 | 1988 | 925 | 0.020 |
Why?
|
Immunotherapy | 1 | 2001 | 4642 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2011 | 960 | 0.020 |
Why?
|
Blotting, Western | 1 | 1992 | 5034 | 0.010 |
Why?
|
Cell Line | 1 | 2018 | 15576 | 0.010 |
Why?
|
Antigens, CD | 1 | 2015 | 3998 | 0.010 |
Why?
|
Genotype | 2 | 2010 | 12978 | 0.010 |
Why?
|
HLA-B Antigens | 1 | 2005 | 317 | 0.010 |
Why?
|
Cross-Sectional Studies | 2 | 2015 | 26049 | 0.010 |
Why?
|
Mutation | 3 | 2005 | 30016 | 0.010 |
Why?
|
Breast Feeding | 1 | 2011 | 1354 | 0.010 |
Why?
|
Logistic Models | 2 | 2012 | 13245 | 0.010 |
Why?
|
T-Lymphocytes | 2 | 1998 | 10175 | 0.010 |
Why?
|
Lung | 2 | 2019 | 9998 | 0.010 |
Why?
|
Cell Separation | 1 | 1988 | 1718 | 0.010 |
Why?
|
Survival Rate | 1 | 1996 | 12719 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 1990 | 2202 | 0.010 |
Why?
|
Infant Mortality | 1 | 2007 | 751 | 0.010 |
Why?
|
Otitis Media | 1 | 1984 | 286 | 0.010 |
Why?
|
Staphylococcus aureus | 1 | 1990 | 1457 | 0.010 |
Why?
|
Squalene | 1 | 2001 | 35 | 0.010 |
Why?
|
Polysorbates | 1 | 2001 | 44 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2011 | 3206 | 0.010 |
Why?
|
HLA-B27 Antigen | 1 | 2001 | 63 | 0.010 |
Why?
|
Antigenic Variation | 1 | 2001 | 118 | 0.010 |
Why?
|
Shock, Septic | 1 | 1988 | 769 | 0.010 |
Why?
|
Vaccines, Subunit | 1 | 2001 | 158 | 0.010 |
Why?
|
Homosexuality, Male | 1 | 2009 | 1333 | 0.010 |
Why?
|
Suspensions | 1 | 2000 | 66 | 0.010 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2000 | 317 | 0.010 |
Why?
|
Capsules | 1 | 2000 | 191 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 1988 | 1971 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2011 | 3822 | 0.010 |
Why?
|
Body Weight | 1 | 2010 | 4614 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2011 | 4533 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 2001 | 712 | 0.010 |
Why?
|
Atovaquone | 1 | 1999 | 56 | 0.010 |
Why?
|
Heart Arrest | 1 | 2009 | 1513 | 0.010 |
Why?
|
Drug Tolerance | 1 | 2000 | 367 | 0.010 |
Why?
|
DNA Primers | 1 | 2003 | 2817 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16571 | 0.010 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2003 | 974 | 0.010 |
Why?
|
Pregnancy Outcome | 1 | 2008 | 2921 | 0.010 |
Why?
|
Peptide Fragments | 2 | 2000 | 5110 | 0.010 |
Why?
|
Zalcitabine | 1 | 1997 | 43 | 0.010 |
Why?
|
Herpesvirus 3, Human | 1 | 1998 | 159 | 0.010 |
Why?
|
Drug Resistance, Microbial | 1 | 2000 | 825 | 0.010 |
Why?
|
Neopterin | 1 | 1997 | 56 | 0.010 |
Why?
|
Gene Expression | 1 | 1990 | 7568 | 0.010 |
Why?
|
Protein Binding | 1 | 2009 | 9345 | 0.010 |
Why?
|
Virus Cultivation | 1 | 1997 | 88 | 0.010 |
Why?
|
Encephalitis | 2 | 1991 | 438 | 0.010 |
Why?
|
Anthropometry | 1 | 2001 | 1338 | 0.010 |
Why?
|
Washington | 1 | 1997 | 315 | 0.010 |
Why?
|
Phospholipases A2 | 1 | 1996 | 197 | 0.010 |
Why?
|
Herpes Zoster | 1 | 1998 | 253 | 0.010 |
Why?
|
Demyelinating Diseases | 1 | 1998 | 352 | 0.010 |
Why?
|
Survival Analysis | 2 | 2003 | 10073 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 2000 | 1739 | 0.010 |
Why?
|
Immunization | 1 | 2000 | 1217 | 0.010 |
Why?
|
Virus Activation | 1 | 1997 | 320 | 0.010 |
Why?
|
Genetic Variation | 1 | 2010 | 6561 | 0.010 |
Why?
|
Interleukin-4 | 1 | 1998 | 1146 | 0.010 |
Why?
|
South Africa | 1 | 2000 | 1836 | 0.010 |
Why?
|
Drug Interactions | 1 | 1999 | 1415 | 0.010 |
Why?
|
Rats, Inbred Lew | 1 | 1996 | 1157 | 0.010 |
Why?
|
Mouth | 1 | 1996 | 381 | 0.010 |
Why?
|
Phylogeny | 1 | 2001 | 2806 | 0.010 |
Why?
|
Pedigree | 1 | 2001 | 4539 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2010 | 7995 | 0.010 |
Why?
|
Energy Intake | 1 | 2001 | 2132 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 1999 | 2079 | 0.010 |
Why?
|
Longitudinal Studies | 2 | 2001 | 14591 | 0.010 |
Why?
|
Eye | 1 | 1996 | 712 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2010 | 11874 | 0.010 |
Why?
|
Base Sequence | 1 | 2003 | 12421 | 0.010 |
Why?
|
Pandemics | 1 | 2012 | 8645 | 0.010 |
Why?
|
Interleukin-2 | 1 | 1998 | 1887 | 0.010 |
Why?
|
Regression Analysis | 1 | 2001 | 6338 | 0.010 |
Why?
|
Recurrence | 2 | 1996 | 8426 | 0.010 |
Why?
|
Brain | 2 | 2014 | 27101 | 0.010 |
Why?
|
Autoimmunity | 1 | 1998 | 1350 | 0.010 |
Why?
|
Enzyme Activation | 1 | 1996 | 3591 | 0.010 |
Why?
|
Antibody Specificity | 1 | 1992 | 1058 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2012 | 15612 | 0.010 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 1991 | 186 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2000 | 5863 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2000 | 6520 | 0.010 |
Why?
|
Drug Resistance | 1 | 1996 | 1594 | 0.010 |
Why?
|
Reperfusion Injury | 1 | 1996 | 1023 | 0.010 |
Why?
|
Electrodes | 1 | 1991 | 610 | 0.000 |
Why?
|
Injections, Intravenous | 1 | 1991 | 1376 | 0.000 |
Why?
|
Mitogens | 1 | 1988 | 229 | 0.000 |
Why?
|
Genetic Predisposition to Disease | 1 | 2010 | 17878 | 0.000 |
Why?
|
Scalp | 1 | 1991 | 389 | 0.000 |
Why?
|
Uganda | 1 | 1992 | 1332 | 0.000 |
Why?
|
Cervix Uteri | 1 | 1991 | 570 | 0.000 |
Why?
|
Boston | 1 | 2000 | 9313 | 0.000 |
Why?
|
HLA-DQ Antigens | 1 | 1987 | 191 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 36402 | 0.000 |
Why?
|
Proportional Hazards Models | 1 | 2000 | 12447 | 0.000 |
Why?
|
Chronic Disease | 1 | 2000 | 9311 | 0.000 |
Why?
|
HLA-DR Antigens | 1 | 1987 | 602 | 0.000 |
Why?
|
Consciousness | 1 | 1991 | 600 | 0.000 |
Why?
|
Osteitis | 1 | 1984 | 33 | 0.000 |
Why?
|
Animals | 3 | 1996 | 168201 | 0.000 |
Why?
|
Petrous Bone | 1 | 1984 | 85 | 0.000 |
Why?
|
Middle Aged | 1 | 2018 | 220584 | 0.000 |
Why?
|
Dogs | 1 | 1988 | 3838 | 0.000 |
Why?
|
Skin | 1 | 1996 | 4473 | 0.000 |
Why?
|
Antigens, Surface | 1 | 1987 | 1605 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 1984 | 20556 | 0.000 |
Why?
|
Aging | 1 | 2000 | 8699 | 0.000 |
Why?
|
Rats | 1 | 1996 | 23717 | 0.000 |
Why?
|
Seizures | 1 | 1991 | 2954 | 0.000 |
Why?
|
Escherichia coli | 1 | 1988 | 4209 | 0.000 |
Why?
|
Acute Disease | 1 | 1984 | 7237 | 0.000 |
Why?
|